1. Home
  2. SAR vs MNPR Comparison

SAR vs MNPR Comparison

Compare SAR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$22.36

Market Cap

361.6M

Sector

Finance

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$59.48

Market Cap

368.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAR
MNPR
Founded
2007
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
361.6M
368.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SAR
MNPR
Price
$22.36
$59.48
Analyst Decision
Hold
Strong Buy
Analyst Count
4
11
Target Price
$23.75
$107.00
AVG Volume (30 Days)
87.5K
168.5K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
14.34%
N/A
EPS Growth
N/A
54.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.39
N/A
P/E Ratio
$9.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.78
$29.18
52 Week High
$25.64
$105.00

Technical Indicators

Market Signals
Indicator
SAR
MNPR
Relative Strength Index (RSI) 47.77 48.81
Support Level $21.58 $51.32
Resistance Level $22.82 $61.51
Average True Range (ATR) 0.39 4.78
MACD 0.02 -0.49
Stochastic Oscillator 50.91 39.71

Price Performance

Historical Comparison
SAR
MNPR

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: